By Christopher Kuo

Edwards Lifesciences raised its full-year outlook after earnings and revenue topped Wall Street forecasts.

The medical technology company on Thursday raised its full-year forecast for sales to $6.5 to $6.9 billion and the expected midpoint of its adjusted earnings per share to $2.95 to $3.05. Analysts polled by FactSet project revenue of $6.68 billion and adjusted earnings of $2.97 a share.

For the second quarter, the company projects sales of $1.66 to $1.74 billion, and adjusted earnings of 70 cents a share to 76 cents a share. Analysts project revenue of $1.68 billion and adjusted earnings of 75 cents.

The company reported a profit of $380.7 million, or 66 cents a share, compared with $358 million, or 61 cents a share, a year earlier.

Adjusted earnings per share were 78 cents a share, above analysts' expectations of 73 cents a share, according to FactSet.

Revenue rose to $1.65 billion from $1.41 billion a year earlier. Analysts were expecting revenue of $1.6 billion.

The company's revenue growth was driven by transcatheter aortic valve replacement sales, which rose 14% to $1.2 billion. Surgical sales rose 10% to $276.2 million.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

April 23, 2026 16:46 ET (20:46 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.